Ovarian cancer: strategies for overcoming resistance to chemotherapy
Top Cited Papers
- 1 July 2003
- journal article
- review article
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 3 (7) , 502-516
- https://doi.org/10.1038/nrc1123
Abstract
Ovarian cancer is responsible for 4% of deaths from cancer in women. Treatment comprises a combination of surgery and chemotherapy, but patients typically experience disease relapse within 2 years of the initial treatment. Further treatment can extend survival, although relapse eventually occurs again. A better understanding of the mechanisms that underlie this drug resistance should allow treatment to be optimized, so that substantial improvements in the outlook for women with this disease can be achieved.Keywords
This publication has 108 references indexed in Scilit:
- Disruption of the Fanconi anemia–BRCA pathway in cisplatin-sensitive ovarian tumorsNature Medicine, 2003
- New paradigms in the treatment of breast and colorectal cancer—an introductionEuropean Journal Of Cancer, 2002
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- Phase II clinical study of BBR 3464, a novel, bifunctional platinum analogue, in patients with advanced ovarian cancerEuropean Journal Of Cancer, 2001
- Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year ResultsJNCI Journal of the National Cancer Institute, 2000
- Pharmacological Rescue of Mutant p53 Conformation and FunctionScience, 1999
- Cellular and molecular determinants of cisplatin resistanceEuropean Journal Of Cancer, 1998
- Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes.Journal of Clinical Investigation, 1997
- hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agentsOncogene, 1997
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996